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Two female patients presented with bullous cutaneous lupus on sun-exposed areas and synovitis, and
tested positive for antinuclear antibodies, anti-Smith (anti-Sm), anti-dsDNA, and low complement levels.
Case 2 also suffered oral ulcers. Thus, diagnoses of bullous systemic lupus erythematosus (BSLE) were
made. Both patients responded distinctly to Tripterygium wilfordii polyglycosidium (T2; 60 mg/day)
combined with oral prednisone (30e40 mg/day), which showed efﬁcacy in 1e2 weeks and produced no
side effects. Therefore, T2 combined with low-dose corticosteroids may be an effective and highly
tolerable alternative for treating BSLE.
Copyright © 2015, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Tripterygium wilfordii polyglycosidium (T2) is a traditional Chinese
medicine widely used in China in organ transplantation and for the
treatment of inﬂammatory and autoimmune diseases, neurode-
generative diseases, and some tumors. Bullous systemic lupus er-
ythematosus (BSLE) is a rare and severe category of systemic lupus
erythematosus (SLE) associated with relative treatment difﬁculty.
Herewe report two female BSLE patients treated effectively with T2
and a low dose of corticosteroids.Case reports
Case 1
A 41-year-old female farmer presentedwith symmetric bullous and
erythematous eruptions on sun-exposed areas. About 6 months
prior, light-sensitive and symmetric violaceous erythema had
occurred on her face and the dorsum of her hands with no obviousy have no ﬁnancial or non-
atter or materials discussed
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al Association. Published by Elsevipredisposing causes. Facial dermatitis was diagnosed in a local
clinic, and intravenous dexamethasone (5 mg/day) was prescribed
for a week. As a result, her lesions disappeared, and the treatment
was discontinued. However, 3 months later, because she had been
working outside for long hours each day, aggravated light-sensitive
and symmetric violaceous erythema reoccurred, with several ves-
icles over it. Arthralgia involving the small joints of the hands,
bilateral wrists, and knees was observed, and the symptoms
worsened in cold temperatures. Mouth or eye dryness, fever,
mucosal ulcer, or Raynaud's phenomenon were not found.
On examination, axillary temperature was 37C. Diffuse in-
ﬂammatory violaceous erythema was observed on her face and the
dorsum of her hands. Multiple tense, clear vesicles appeared on the
upper part of her cheeks and nose, over the erythematous base.
Nikolsky's sign was negative. In addition, superﬁcial crusting,
postinﬂammatory hyperpigmentation, and small superﬁcial scars
on the dorsum of her hands were noted (Figures 1A and 1B).
Tenderness on the small joints of the hands, bilateral wrists, and
knees was positive. No further abnormal systemic examinationwas
conducted.
Routine blood and urine tests were normal. Autoimmunity tests
were positive for antinuclear antibodies (ANA; 1:640; using HEp-2
cells); anti-dsDNA, anti-Smith (anti-Sm), anti-Sj€ogren's syndrome-
related antigen A (anti-SSA), and anti-SSB; and low levels of C3
[0.56 g/L (0.78e2.1 g/L)], C4 [0.10 g/L (0.17e0.4 g/L)], and hemolytic
complement [CH50; 70 g/L (90e180 g/L)]. They were negative for
rheumatoid factors and antiphospholipid antibodies. Theer Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Figure 1 Patient 1: (A, B) A 41-year-old female with violaceous erythema diffused on her face and the dorsum of her hands. Multiple tense and clear vesicles dispersed on the upper
part of her cheeks and nose. Nikolsky's sign was negative. (C) Histopathology of the facial vesicles revealed a subepidermal split, liquefaction of basal cells, a neutrophilic
microabscess in the dermal papillae, and mild inﬁltration of neutrophils and histocytes around vessels and cutaneous appendages (hematoxylineeosin; original
magniﬁcation 100). (D) Direct immunoﬂuorescence revealed granular immunoglobulin G deposition along the basement membrane zone (original magniﬁcation 400). (E, F)
After the combined treatment of Tripterygium wilfordii polyglycosidium and low-dose prednisone for 6 months, hyperpigmentation was left on her face and the dorsum of her
hands.
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hour). A biopsy of the facial vesicles revealed a subepidermal split,
liquefaction of basal cells, a neutrophilic microabscess in the
dermal papillae, and mild inﬁltration of neutrophils and histocytes
around vessels and cutaneous appendages (Figure 1C). Direct
immunoﬂuorescence (DIF) revealed immunoglobulin G and C3
deposition along the basement membrane zone (Figure 1D).
A diagnosis of BSLE was considered. Resting, keeping warm, and
avoiding sunshine were advised. Oral prednisone (30 mg/day), T2
(60 mg/day), and calcium supplements were prescribed. Two
weeks into the treatment, the inﬂammatory violaceous erythema
on sun-exposed areas darkened, and arthralgia dissipated. The skin
eruptions improved and arthralgia of all involved joints dis-
appearedwithin 2months. Oral prednisone and T2were reduced to
20 mg/day and 40 mg/day, respectively. By the 4th month, her skin
eruptions had almost vanished (Figures 1E and 1F), and arthralgia
did not relapse. T2 was discontinued, and prednisonewas gradually
reduced to 10 mg/day. Serological ANA decreased to 1:80, and C3,
C4, and CH50 recovered, although anti-dsDNA, anti-Sm, anti-SSA,
and anti-SSB were still positive. No side effects were reported.Case 2
A 42-year-old female farmer presented with violaceous erythema
and vesicles on sun-exposed areas. Like Case 1, she had erythem-
atous and vesicular rashes on her face, neck, and extremities for
about 2 weeks because of much sun-exposed farming. She also
complained of fever, fatigue, pruritus, painful oral ulcer, and
arthralgia involving the knees and ankles. Other systemic symp-
toms were not found.
On examination, axillary temperature was 37.8C. Sporadic
violaceous vesiculopapules, erythema, discoid plaques, and tense
bullae based on the erythema or plaques were seen on her face,
neck, and distal extremities. Some vesicles were ruptured and
crusted. Nikolsky's sign was negative (Figures 2A and 2B). Oralulcers could be seen, while other mucosae were unaffected.
Tenderness on the bilateral knees and ankles was found, but
additional abnormal systemic problems were not.
The blood cell count was normal. Urine protein was 2þ. The ESR
was 60 mm/hour. Autoimmunity indices were positive for ANA
(1:1280); anti-dsDNA and anti-Sm; and low levels of C3 (0.46 g/L),
C4 (0.12 g/L), and CH50 (50 g/L) were noted. A biopsy of a vesicle on
the left arm and DIF showed similar results to those of Case 1. A
renal biopsy was rejected.
BSLE was diagnosed. Oral prednisone (40 mg/day), T2 (60 mg/
day), calcium supplements, and ethacridine lactate paste for the
eruptions were prescribed. After 1 week, the vesicles on sun-
exposed areas decreased, and arthralgia began to dissipate. Urine
protein returned to normal. Oral prednisone was then reduced to
30 mg/day. By the end of the 1st month, the skin eruptions and
arthralgia of all involved joints greatly improved. The drugs were
further downregulateddprednisone to 20mg/day and T2 to 40mg/
day. The skin eruptions and arthralgia resolved. After 2 months, T2
was discontinued, and prednisone was gradually decreased to
10 mg/day. By the 6th month, hyperpigmentation was left on the
original eruptions (Figures 2C and 2D), and no more arthralgia was
found. Urine protein was negative and ANA 1:40, C3, C4, and CH50
returned to normal, but anti-dsDNA, anti-Sm, anti-SSA, and anti-
SSB were still positive. No side effects were reported.Discussion
BSLE is a form of subepidermal autoimmune bullous dermatosis, a
rare entity that accounts for less than 5% of SLE. Females in their 20s
to 40s have high chances of being diagnosed with BSLE.1 Etiology is
unclear. Genetics and autoimmunity for VII collagen in the base-
ment membrane zone may take part in the separation of the
epidermis and dermis. The most common presentation of BSLE is
asymptomatic tense blisters conﬁned to sun-exposed areas or
sometimes present in a more widespread distribution. Multisystem
Figure 2 Patient 2: (A, B) A 42-year-old female with sporadic violaceous vesiculopapules, erythema, discoid plaques, and tense bullae based on the erythema or plaques distributed
on her face and distal upper extremities. Some vesicles were ruptured and crusted. Nikolsky's sign was negative. (C, D) Hyperpigmentation and crusting were left after a combined
treatment of T2 and low-dose prednisone for 6 months.
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pathological manifestation of vesicles is similar to that of dermatitis
herpetiformis, characterized by a subepidermal split and neutro-
philic inﬁltration of the papillary dermis. DIF is positive for depo-
sition of immunoglobulin G, M, or A along the basementmembrane
zone. Both our patients ﬁt the criteria for SLE of the Systemic Lupus
International Collaborating Clinics,2 presenting with bullous cuta-
neous lupus and synovitis, and testing positive for ANA, anti-Sm,
anti-dsDNA, and low complement levels. Case 2 also suffered oral
ulcers.
Common treatment options include dapsone, high-dose corti-
costeroids, antimalarial drugs, immunosuppressants, and biologic
drugs.1,3 BSLE responds well to dapsone, but purchasing dapsone in
China is difﬁcult because of a halt in production, so corticoid hor-
mones at a high dose or in combination with immunosuppressants
are the primary option. However, BSLE patients often resist these
treatments.3
T. wilfordiiHook F. (TwHF), also known as thunder god vine or lei
gong teng, is a traditional Chinese herb that has attracted great
interest around the world. The extract from its woody root,
T. wilfordii multiglycoside, also known as T2 or TII, is one of the
most widely used TwHF preparations in China. T2 contains
different concentrations of therapeutically active compounds,
including diterpenoids, alkaloids, triterpenoids, and glycosides.
Diterpenoids, especially triptolide and tripdiolide, play the major
anti-inﬂammatory and immunosuppressive roles by inhibiting the
proliferation and inducing the apoptosis of T and B cells; reducing
the production of cytokines, transcription factors, and adhesion
molecules; and suppressing pro-inﬂammatory enzymes.4,5 T2 has
been widely used in China as a cheap and effective drug to treat abroad spectrum of dermatoses, such as generalized eczema, atopic
dermatitis, vasculitis, psoriasis, SLE,6 and pemphigus. Themain side
effects include digestive tract reactions, leukocytopenia, hepatic
and renal dysfunction, antifertility, and paramenia, which are
mostly reversible if T2 is discontinued in time. Therefore, regular
laboratory examination of the blood cell count and the liver and
renal function indices is recommended.
Both patients responded distinctly to T2 combined with low-
dose prednisone, which showed efﬁcacy in 1e2 weeks and
exhibited good control in half a year. Case 2 was complicated at the
ﬁrst visit by urine protein, which tested negative after 1 week of
treatment and has remained negative since, so it is unclear whether
kidney damage really existed or the treatment just dramatically
worked. In clinical trials, T2 is frequently combined with steroids
for treating systemic diseases. The combined treatments usually
produce better symptomatic reduction with fewer adverse re-
actions than any single high-dose treatment.7e11 Triptolide binds to
the glucocorticoid receptor. The glucocorticoid receptoretriptolide
complex cannot activate glucocorticoid-responsive genes and may
suppress the transcriptional activity of nuclear factor kappa B (NF-
kB) and activator protein 1 (AP-1), producing a combination of anti-
inﬂammatory and steroid-sparing effects. A hypothesis has been
proposed that a combined remedy of TwHF and corticosteroids
enhances the therapeutic efﬁcacy and reduces the side effects of
the corticosteroids.
However, there is insufﬁcient evidence to assess if T2 was as
effective as prednisone, dapsone, and other immunosuppressants
in the patients with BSLE. More methodologically powered studies
are needed to better inform management options for the use of T2
for BSLE.
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Both cases with BSLE responded effectively and safely to a com-
bined treatment of T2 and low-dose corticosteroids. However,
studies with large samples are needed before any meaningful
conclusions can be drawn.
References
1. Contestable JJ, Edhegard KD, Meyerle JH. Bullous systemic lupus erythemato-
sus: a review and update to diagnosis and treatment. Am J Clin Dermatol
2014;15:517e24.
2. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic
Lupus International Collaborating Clinics classiﬁcation criteria for systemic
lupus erythematosus. Arthritis Rheum 2012;64:2677e86.
3. Duan L, Chen L, Zhong S, et al. Treatment of bullous systemic lupus erythe-
matosus. J Immunol Res 2015;2015:167064.
4. Brinker AM, Ma J, Lipsky PE, Raskin I. Medicinal chemistry and pharmacology of
genus Tripterygium (Celastraceae). Phytochemistry 2007;68:732e66.5. Tao X, Cai JJ, Lipsky PE. The identity of immunosuppressive components of the
ethyl acetate extract and chloroform methanol extract (T2) of Tripterygium
wilfordii Hook F. J Pharmacol Exp Ther 1995;272:1305e12.
6. Patavino T, Brady DM. Natural medicine and nutritional therapy as an alter-
native treatment in systemic lupus erythematosus. Altern Med Rev 2001;6:
460e71.
7. Li ZX, Tan H, Xiong XJ. Clinical effect of Tripterygiitotorum combined with
prednisone and its effect on serum IL-6 level in treating patients with
myasthenia gravis. Zhongguo Zhong Xi Yi Jie He Za Zhi 2002;22:175e7 [In
Chinese].
8. Wu YJ, Lao ZY, Zhang ZL. Clinical observation on small doses Tripterygium
wilfordii polyglycoside combined with methotrexate in treating rheumatoid
arthritis. Zhongguo Zhong Xi Yi Jie He Za Zhi 2001;21:895e6 [In Chinese].
9. Wang J, Wang YT, Shao JQ, Wang X, Du H. Immunosuppressive therapies in
patients with Graves' ophthalmopathy. Zhonghua Nei Ke Za Zhi 2004;43:125e7
[In Chinese].
10. Li LF. Treatment of pyoderma gangrenosum with oral Tripterygium wilfordii
multiglycoside. J Dermatol 2000;27:478e81.
11. Xu G, Tu W, Jiang D, Xu C. Tripterygium wilfordii Hook F treatment for idiopathic
refractory nephrotic syndrome in adults: a meta-analysis. Nephron Clin Pract
2009;111:c223e8.
